DAIICHI SANKYO COMPANY,LIMITED (4568.T) Latest Company News

Sep 2, 2026, 09:17 UTC
Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.
Source:
- nikkei.com
Sep 2, 2026, 04:52 UTC
Daiichi Sankyo announced that the European Union granted a partial change approval for the combination therapy of Enhertu and pertuzumab as first-line treatment for breast cancer patients.
Source:
Aug 31, 2026, 13:00 UTC
The Delhi High Court ordered a forensic audit into the dissipation of Fortis shares and assets linked to former Fortis promoters Malvinder Mohan Singh and Shivinder Mohan Singh in the Daiichi Sankyo enforcement case, appointing S Ramanand Aiyar & Co. as the forensic auditor.
Source:
Aug 27, 2026, 01:04 UTC
Daiichi Sankyo announced the establishment of a new commercialization unit effective April 1, consolidating and reorganizing its global commercialization structure, with Ken Keller appointed as Chief Commercialization Officer.
Source:
- nikkei.com
Aug 18, 2026, 03:34 UTC
Daiichi Sankyo announced positive results from a global Phase 3 clinical trial of its cancer drug Enhertu for first-line treatment of HER2-mutant non-small cell lung cancer, showing statistically significant and clinically meaningful improvement in the primary endpoint with no new safety concerns.
Source:
Aug 12, 2026, 07:36 UTC
Daiichi Sankyo announced that its drug Enhertu (trastuzumab deruxtecan) in combination with pertuzumab received approval in China for first-line treatment of unresectable or metastatic HER2-positive breast cancer in adults.
Jul 14, 2026, 11:00 UTC
FRONTEO and Daiichi Sankyo jointly develop a predictive model that automatically extracts toxicological interpretations from toxicity study reports, presented at the 53rd Annual Meeting of the Japanese Society of Toxicology.
Source:
- s.kabutan.jp
- s.kabutan.jp

4568.T

Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.

Daiichi Sankyo announced that the European Union granted a partial change approval for the combination therapy of Enhertu and pertuzumab as first-line treatment for breast cancer patients.

The Delhi High Court ordered a forensic audit into the dissipation of Fortis shares and assets linked to former Fortis promoters Malvinder Mohan Singh and Shivinder Mohan Singh in the Daiichi Sankyo enforcement case, appointing S Ramanand Aiyar & Co. as the forensic auditor.

Daiichi Sankyo announced the establishment of a new commercialization unit effective April 1, consolidating and reorganizing its global commercialization structure, with Ken Keller appointed as Chief Commercialization Officer.

Daiichi Sankyo announced positive results from a global Phase 3 clinical trial of its cancer drug Enhertu for first-line treatment of HER2-mutant non-small cell lung cancer, showing statistically significant and clinically meaningful improvement in the primary endpoint with no new safety concerns.

Daiichi Sankyo announced that its drug Enhertu (trastuzumab deruxtecan) in combination with pertuzumab received approval in China for first-line treatment of unresectable or metastatic HER2-positive breast cancer in adults.

FRONTEO and Daiichi Sankyo jointly develop a predictive model that automatically extracts toxicological interpretations from toxicity study reports, presented at the 53rd Annual Meeting of the Japanese Society of Toxicology.